Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC
Abstract Background Stereotactic ablative radiotherapy (SABR) is thought to activate T cell responses in patients with cancer, leading to its combination with immunotherapy and chemotherapy for treatment of non-small-cell lung cancer (NSCLC). Here, we aimed to provide a high-resolution transcriptomi...
Saved in:
Main Authors: | Chao Liu, Yanjuan Chen, Xiaohui Li, Zhijie Bai, Meilin Jiang, Dongsheng Sheng, Wenxue Zou, Rui Huang, Qingyu Huang, Fuhao Wang, Jingyang Zhu, Huiru Sun, Bing Liu, Zongcheng Li, Bing Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-02-01
|
Series: | Cancer Immunology, Immunotherapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00262-024-03935-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Partial Stereotactic Ablative Radiotherapy Boost Before Conventional Radiotherapy (P‐SABR) for Large (> 5 cm) Unresectable Stage III Nonsmall Cell Lung Cancer
by: Yun Bai, et al.
Published: (2025-01-01) -
The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
by: Steven Eric Finkelstein, et al.
Published: (2011-01-01) -
TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology
by: Jing Lu, et al.
Published: (2025-03-01) -
SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer
by: Qingyu Huang, et al.
Published: (2025-02-01) -
CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors
by: Olga R. Brook, et al.
Published: (2015-01-01)